Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosisOur pipeline
Discovering targeted medicines
Our lead asset, zelasudil (RXC007), a next-generation selective ROCK2 inhibitor, with potential in multiple interstitial lung diseases and cancer-associated fibrosis is in a Phase 2 clinical programme with an initial indication in idiopathic pulmonary fibrosis. We have a further programme in our ROCK portfolio, RXC008, a potential first-in-class GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease, which is expected to enter the clinic in early 2024. Our lead oncology asset, zamaporvint (RXC004), is in a Phase 2 clinical programme for patients with Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy. In discovery, we have a pipeline of rapidly advancing research programmes and collaborations, driven by our world-class drug discovery engine.
Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets. These strengths have been recognised by others, and we have successfully completed a number of partnering deals in recent years including:
- AstraZeneca (Porcupine inhibitor, AZD5055 previously RXC006) – now in Phase 1 clinical studies (out-licensed with milestones)
- Jazz Pharmaceuticals (Pan-RAF inhibitor, JZP815) – now in Phase 1 clinical studies (sold with milestones)
- Jazz Pharmaceuticals, ongoing oncology research collaboration in MAPK pathway
- Loxo Oncology /Eli Lilly (BTK inhibitor, JaypircaTM, pirtobrutinib/LOXO-305, previously RXC005) – FDA approved (sold, no further milestones)
Our notable team of in-house scientists is based at our headquarters at Alderley Park, Cheshire, the UK’s largest single site life science campus*. The team combines world-class skills in medicinal chemistry and translational science with deep-rooted biotech and large pharma experience, and has successfully generated numerous drug candidates and progressed them through discovery and into the clinic.
Business model & strategy
Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. Our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.
We are building a leading biotechnology company through the development of novel and differentiated targeted medicines in cancer and fibrotic disease, and the emerging area of cancer-associated fibrosis, where we see the opportunity to be best-in-class, or first-in-class.
Our validated discovery engine fuels our business model and incorporates our in-house experience and extensive network of specialist contractors.
Our distinctive approach consistently enables us to generate, potential best-in-class or first-in-class drug candidates and is built around three steps:
With the goal of de-risking our programmes, we select biologically or clinically validated targets where we believe there is an opportunity to successfully apply our drug discovery capabilities in diseases of high unmet medical need.
Create molecules with differentiated properties, leveraging our design frameworks and our strength and experience in medicinal chemistry and translational biology to optimise a novel differentiated molecule for the target.
Focus our differentiated, targeted small molecules towards commercially attractive markets in which we believe we can be successful.